SynthesisThe Cochrane database of systematic reviews2000
Benzodiazepines for neuroleptic-induced tardive dyskinesia.
Synthesis in The Cochrane database of systematic reviews, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Vitamin E for antipsychotic-induced tardive dyskinesia.The Cochrane database of systematic reviews · 2018Pooled it
Corrections and comments
- Updated by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTardive dyskinesia (TD) is a potentially disfiguring movement disorder of the orofacial region often caused by use of neuroleptic drugs. A wide range of strategies have been used to help manage TD and, for those who are unable to have their antipsychotic medication stopped or substantially changed, the benzodiazapine group of drugs has been suggested as a useful adjunctive treatment.
objectivesTo determine the clinical efficacy of benzodiazepines for people with neuroleptic-induced tardive dyskinesia (TD) schizophrenia or other chronic mental illnesses. SEARCH STRATEGY: Electronic searches of Biological Abstracts (1982-1995), the Cochrane Schizophrenia Group's Register of trials (1995), EMBASE (1980-1995), LILACS (1982-1995), MEDLINE (1966-1995), PsycLIT (1974-1995), SCISEARCH (1995) and handsearching the references of all identified studies. SELECTION CRITERIA: The inclusion criteria for all randomised studies were that they should focus on people with schizophrenia or other chronic mental illnesses and neuroleptic-induced TD and compare the use of benzodiazepines to placebo or no intervention. DATA COLLECTION AND ANALYSIS: The reviewers extracted the data independently and the odds ratio (95% CI) or the average difference (95% CI) were estimated. The reviewers assumed that people who dropped out had no improvement. MAIN
resultsTwo trials were able to be included in this review. The results of this review do not allow any confident interpretations on the clinical utility of benzodiazepines for the treatment of neuroleptic-induced TD. From the data combined in this review, benzodiazepines have no distinct advantages over placebo in the treatment of TD. Data on side effects were not reported in the included trials. REVIEWER'S
conclusionsNo clear statement about the efficacy of benzodiazepines drugs, to treat neuroleptic-induced TD, could be provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.